Ein Pressesprecher von GWPH erwiederte daraufhin sichtlich empört: "We think it is a terrible shame that, because of cost-cutting presented as science, MS patients in England are being denied a treatment which works in many cases," "It is sad that it should be put out of the reach of many patients in the very county where it was developed."